FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Fulgent Genetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$20.10+0.29 (+1.46%)
Close on Oct 19, 2026
- Market cap
- $562.90M
- P/E (TTM)
- –
- Dividend yield
- –
Fulgent Genetics, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory Services | $323.37M | $319.81M | $322.22M | $315.41M | $303.22M | $292.45M | $283.47M | $277.76M | $290.71M | $287.53M | $289.21M | – | 99.8% | +6.6% |
| Therapeutic Development | $564.00K | $534.00K | $447.00K | $138.00K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – | 0.2% | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic Development | -$20.14M | -$20.05M | -$19.85M | -$19.57M | -$17.39M | -$17.25M | -$16.56M | -$11.18M | -$10.72M | -$9.49M | -$7.67M | – | +15.8% |
| Laboratory Services | -$34.36M | -$19.72M | -$7.21M | -$2.62M | -$5.45M | -$3.19M | -$4.91M | -$182.00K | $3.73M | -$12.01M | -$16.86M | – | +529.9% |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $295.92M | $293.83M | $296.55M | $291.72M | $279.82M | $267.80M | $259.13M | $252.64M | $265.91M | $264.77M | $268.98M | $266.43M | 91.4% | +5.8% |
| Foreign | $28.01M | $26.51M | $26.12M | $23.83M | $23.41M | $24.65M | $24.34M | $25.12M | $24.80M | $22.77M | $20.24M | $19.98M | 8.6% | +19.7% |
| Other countries | $14.52M | $13.66M | $13.21M | $12.41M | $12.33M | $13.50M | $11.70M | $12.52M | $11.55M | $9.30M | $8.79M | – | 4.5% | +17.7% |
| China | $13.53M | $12.85M | $12.91M | $11.42M | $11.08M | $11.15M | $12.64M | $12.60M | $13.25M | $13.46M | $11.45M | – | 4.2% | +22.1% |
From the segment and revenue-disaggregation notes of Fulgent Genetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.